Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Last trade$1.62
Day change-$0.05 (-2.99%)
Day range$1.49 – $1.86
Volume26,687
Market cap$83M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$83.24M
Price / earnings
—
Price / book
10.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.22×
Profitability
Earnings per share
-$0.15
Return on assets
-84.23%
Return on equity
-95.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.62×
Quick ratio
8.62×
Cash ratio
8.45×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.42M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PLYX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$877K
$661K
$1.28M
Research and development
$2.45M
$719K
$679K
Total operating expenses
$3.33M
$1.38M
$1.96M
Operating income
-$3.33M
-$1.38M
-$1.96M
Interest expense
$0
$0
$0
Income before taxes
-$3.33M
-$1.38M
-$2.54M
Income taxes
$0
$0
$0
Net income
-$3.33M
-$1.38M
-$2.54M
Net income attributable to common shareholders
-$3.33M
-$1.38M
-$2.54M
EBITDA
-$3.33M
-$1.38M
-$1.96M
Basic earnings per share
-$0.07
-$0.03
-$0.05
Diluted earnings per share
-$0.07
-$0.03
-$0.05
Recent news
Company coverage with links to the original publishers.
Polaryx Therapeutics (PLYX) announced it remains on schedule to initiate its Phase 2 SOTERIA basket trial in the fourth quarter of 2026, evaluating lead candidate PLX-200 across four rare pediatric lysosomal storage disorders. The company has secured FDA authorization, engaged a CRO, obtained Fast Track Designation across all four indications, and completed a $10 million financing to support trial initiation and clinical milestones.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.